3-benzazecine-based cyclic allene derivatives as highly potent P-glycoprotein inhibitors overcoming doxorubicin multidrug resistance

Aim: Enamino 3-benzazecine compounds, incorporating the C6-C8 allene system, were synthesized and evaluated in vitro as inhibitors of P-glycoprotein (P-gp) and/or multidrug resistance-associated protein 1 (MRP1), two efflux pumps mainly connected with multidrug resistance (MDR) in cancer cells. Results & methodology: Most of the synthesized compounds were selective P-gp inhibitors in Calcein-AM uptake assay. Structure-activity relationships (SARs) pointed out that CO2Me derivatives are more potent than acetyl derivatives, and 10,11-dimethoxy compounds are five to tenfold more potent inhibitors than the respective unsubstituted compounds, and that the P-gp inhibition potency is mainly related to volume parameters. Conclusion: Nanomolar P-gp inhibitors, such as 23 (IC50 = 4.2 nM), restored the antiproliferative activity of doxorubicin in multidrug-resistant cells. The observed activities showed that 3-benzazecine-based compounds may be promising MDR reversers.

Authors
Titov A.A. 1 , Niso M.2 , Candia M.2 , Kobzev M.S. 1 , Varlamov A.V. 1 , Borisova T.N. 1 , Voskressensky L.G. 1 , Colabufo N.A.2 , Cellamare S.2 , Pisani L.2 , Altomare C.D.2
Publisher
NLM (Medline)
Number of issue
16
Language
English
Pages
2095-2106
Status
Published
Volume
11
Year
2019
Organizations
  • 1 Organic Chemistry Department, Peoples' Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya St.Moscow 117198, Russian Federation
  • 2 Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Via E. Orabona 4Bari 70125, Italy
Keywords
benzazecine allenes; cytotoxicity; multidrug resistance; multidrug resistance-associated protein 1; p-glycoprotein; structure–activity relationships
Date of creation
24.12.2019
Date of change
24.12.2019
Short link
https://repository.rudn.ru/en/records/article/record/55114/
Share

Other records

Azova M.M., Ahmed A.A., Blagonravov M.L., Ait Aissa A.
Bulletin of Experimental Biology and Medicine. New York Consultants BureauSpringer / Автономная некоммерческая организация Издательство Российской академии медицинских наук. Vol. 167. 2019. P. 475-478